NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

Follow-up over 10 years may show different patterns, and experts predict DCBs will likely be useful in certain populations.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.